Suppr超能文献

与减肥药相关的心脏瓣膜疾病:梅奥诊所超声心动图实验室经验

Diet drug-related cardiac valve disease: the Mayo Clinic echocardiographic laboratory experience.

作者信息

Teramae C Y, Connolly H M, Grogan M, Miller F A

机构信息

Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic Rochester, MN 55905, USA.

出版信息

Mayo Clin Proc. 2000 May;75(5):456-61. doi: 10.4065/75.5.456.

Abstract

OBJECTIVE

To describe the prevalence of diet drug-related valvular disease among our referral population and the association of valvular disease with duration of exposure to fenfluramine and phentermine in combination and to dexfenfluramine alone.

PATIENTS AND METHODS

In this retrospective review of clinical and echocardiographic data, charts of patients referred for treatment of toxic effects of diet drugs were reviewed, and telephone interviews were conducted.

RESULTS

Between June and December 1997, 191 patients (164 women, 27 men; mean age, 47 years) were referred for possible diet drug-related valvular disease. Twenty-eight (28%) of the 99 asymptomatic patients and 40 (43%) of the 92 symptomatic patients had abnormal echocardiographic findings. Valvular lesions among the 68 patients with abnormal echocardiographic findings included mild (or greater) aortic regurgitation in 55 patients (81%), moderate (or greater) mitral regurgitation in 12 (18%), and moderate (or greater) tricuspid regurgitation in 7 (10%). The Food and Drug Administration case definition of diet drug-related valvulopathy was noted in 31 % of this referral population. Of patients with valvulopathy, mean duration of therapy with fenfluramine and phentermine in combination and dexfenfluramine alone was 9 months and 5 months, respectively. Duration of therapy was not associated with presence or absence of disease. Five patients had surgical intervention for severe valvulopathy: 3 had mitral valve repair, 1 had mitral valve replacement, and 1 had aortic valve replacement. Pulmonary hypertension (>40 mm Hg) was found in 24 patients (13%), and 17 (71 %) had pulmonary hypertension in association with valvulopathy.

CONCLUSION

This study demonstrated a 31% (60/191) prevalence of valvulopathy in patients with a history of diet drug exposure who were referred for echocardiographic evaluation. The most common finding was mild aortic regurgitation. Twenty-eight percent of asymptomatic patients had abnormal echocardiographic findings. This study emphasizes the spectrum of diet drug-related cardiac disease and the potential for valvulopathy in asymptomatic patients.

摘要

目的

描述在我们的转诊人群中与减肥药相关的瓣膜病的患病率,以及瓣膜病与联合使用芬氟拉明和苯丁胺以及单独使用右芬氟拉明的暴露持续时间之间的关联。

患者与方法

在这项对临床和超声心动图数据的回顾性研究中,对因减肥药毒性作用前来就诊的患者病历进行了审查,并进行了电话访谈。

结果

1997年6月至12月期间,191例患者(164名女性,27名男性;平均年龄47岁)因可能与减肥药相关的瓣膜病前来就诊。99例无症状患者中有28例(28%)以及92例有症状患者中有40例(43%)超声心动图检查结果异常。68例超声心动图检查结果异常的患者中,瓣膜病变包括55例(81%)轻度(或更严重)主动脉反流、12例(18%)中度(或更严重)二尖瓣反流以及7例(10%)中度(或更严重)三尖瓣反流。在该转诊人群中,31%的患者符合美国食品药品监督管理局关于减肥药相关瓣膜病的病例定义。有瓣膜病的患者中,联合使用芬氟拉明和苯丁胺以及单独使用右芬氟拉明的平均治疗时间分别为9个月和五个月。治疗持续时间与疾病的有无无关。5例患者因严重瓣膜病接受了手术干预:3例行二尖瓣修复术,1例行二尖瓣置换术,1例行主动脉瓣置换术。24例患者(13%)发现有肺动脉高压(>40 mmHg),其中17例(71%)的肺动脉高压与瓣膜病有关。

结论

本研究表明,在因超声心动图评估而转诊的有减肥药暴露史的患者中,瓣膜病的患病率为31%(60/191)。最常见的发现是轻度主动脉反流。28%的无症状患者超声心动图检查结果异常。本研究强调了与减肥药相关的心脏病谱以及无症状患者发生瓣膜病的可能性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验